CCM
ABMD

Chilton Capital Management’s Abiomed Inc ABMD Stock Holding History

Chilton Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7
Closed -$2K – 654
2022
Q2 		$2K Buy
+7
New +$1.89K ﹤0.01% 598
2022
Q1 		– Sell
-7
Closed -$3K – 650
2021
Q4 		$3K Buy
+7
New +$2.37K ﹤0.01% 598
2018
Q2 		– Sell
-9,451
Closed -$2.72M – 225
2018
Q1 		$2.72M Buy
+9,451
New +$2.4M 0.25% 87

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Chilton Capital Management's ABMD Position: Q3 2022 in Review

Chilton Capital Management sold out of Abiomed Inc (ABMD) in Q3 2022, closing a stake of 7 shares — an estimated $2K sold.

Chilton Capital Management first reported a position in ABMD in Q1 2018 and held it in 3 quarters. The position peaked at $2.72M in Q1 2018. 517 funds tracked by Wall St. Rank hold ABMD as of Q3 2022.

  • Chilton Capital Management reported no remaining Abiomed Inc position as of Q3 2022 after selling out during the quarter.
  • Chilton Capital Management sold 7 Abiomed Inc shares in Q3 2022, an estimated $2K.
  • Chilton Capital Management first reported a position in Abiomed Inc in Q1 2018 and held it in 3 quarters.
  • Chilton Capital Management's Abiomed Inc position peaked at $2.72M in Q1 2018.
  • 517 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2022.

Based on Chilton Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.